S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
The UAE holds a major oil and gas conference just ahead of hosting UN COP28 climate talks in Dubai
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
The UAE holds a major oil and gas conference just ahead of hosting UN COP28 climate talks in Dubai
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
The UAE holds a major oil and gas conference just ahead of hosting UN COP28 climate talks in Dubai
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
The UAE holds a major oil and gas conference just ahead of hosting UN COP28 climate talks in Dubai
NASDAQ:ABMD

Abiomed (ABMD) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$381.02
$381.02
50-Day Range
$377.20
$381.30
52-Week Range
$219.85
$381.99
Volume
258 shs
Average Volume
611,028 shs
Market Capitalization
$17.18 billion
P/E Ratio
65.47
Dividend Yield
N/A
Price Target
$362.00

Abiomed MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
5.0% Downside
$362.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.79
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
19.21%
From $4.58 to $5.46 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

692nd out of 970 stocks

Surgical & Medical Instruments Industry

77th out of 99 stocks


ABMD stock logo

About Abiomed (NASDAQ:ABMD) Stock

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.


ABMD Stock News Headlines

[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
This Big Pharma Stock Is a Clear Buy in 2023
3 Powerhouse Stocks to Buy in 2023
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
3 S&P 500 Stocks to Buy If You Like Winning
3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio
10 Best Performing Stocks in November
This Monster Dividend Stock Isn't Done Growing
Why Is Abiomed (ABMD) Up 1.2% Since Last Earnings Report?
Abiomed (ABMD) Q2 Earnings Top Estimates, Margins Down
Why Is Abiomed (ABMD) Stock Up 50% Today?
See More Headlines
Receive ABMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abiomed and its competitors with MarketBeat's FREE daily newsletter.

ABMD Company Calendar

Last Earnings
10/27/2021
Today
10/01/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ABMD
CUSIP
00365410
Employees
2,003
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$362.00
High Stock Price Forecast
$388.00
Low Stock Price Forecast
$300.00
Forecasted Upside/Downside
-5.0%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$136.51 million
Pretax Margin
31.76%

Debt

Sales & Book Value

Annual Sales
$1.03 billion
Cash Flow
$5.09 per share
Book Value
$33.03 per share

Miscellaneous

Free Float
43,964,000
Market Cap
$17.18 billion
Optionable
Optionable
Beta
1.40

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Michael R. MinogueMr. Michael R. Minogue (Age 56)
    Chairman, CEO & Pres
    Comp: $3.04M
  • Mr. Todd A. TrappMr. Todd A. Trapp (Age 52)
    Exec. VP & CFO
    Comp: $914.93k
  • Mr. Marc A. BeganMr. Marc A. Began (Age 56)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $818.64k
  • Mr. Andrew J. GreenfieldMr. Andrew J. Greenfield (Age 50)
    Exec. VP & Chief Commercial Officer
    Comp: $804.95k
  • Dr. David M. Weber Ph.D. (Age 62)
    Scientific & Technology Advisor
    Comp: $1.02M
  • Mr. Matthew T. Plano (Age 58)
    Exec. VP of Global Operations & Integration
  • Dr. Thorsten Siess Ph.D.
    Exec. VP & Chief Technology Officer
  • Ms. Ingrid Goldberg Ward
    Director of Investor Relations
  • Sarah Karr
    Communications Mang.
  • Mr. Michael G. Howley (Age 59)
    VP & GM of Global Sales













ABMD Stock - Frequently Asked Questions

Should I buy or sell Abiomed stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abiomed in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ABMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares.
View ABMD analyst ratings
or view top-rated stocks.

What is Abiomed's stock price forecast for 2023?

5 brokerages have issued 1 year price objectives for Abiomed's stock. Their ABMD share price forecasts range from $300.00 to $388.00. On average, they expect the company's stock price to reach $362.00 in the next year. This suggests that the stock has a possible downside of 5.0%.
View analysts price targets for ABMD
or view top-rated stocks among Wall Street analysts.

How were Abiomed's earnings last quarter?

Abiomed, Inc. (NASDAQ:ABMD) released its earnings results on Wednesday, October, 27th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $0.98 by $0.05. The medical equipment provider earned $248.10 million during the quarter, compared to analysts' expectations of $248.06 million. Abiomed had a net margin of 24.84% and a trailing twelve-month return on equity of 14.77%. The business's revenue was up 18.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.01 earnings per share.
Read the conference call transcript
.

What is Michael R. Minogue's approval rating as Abiomed's CEO?

96 employees have rated Abiomed Chief Executive Officer Michael R. Minogue on Glassdoor.com. Michael R. Minogue has an approval rating of 72% among the company's employees.

What other stocks do shareholders of Abiomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Block (SQ), Netflix (NFLX), Adobe (ADBE) and Salesforce (CRM).

What is Abiomed's stock symbol?

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

What is Abiomed's stock price today?

One share of ABMD stock can currently be purchased for approximately $381.02.

How much money does Abiomed make?

Abiomed (NASDAQ:ABMD) has a market capitalization of $17.18 billion and generates $1.03 billion in revenue each year. The medical equipment provider earns $136.51 million in net income (profit) each year or $5.82 on an earnings per share basis.

How many employees does Abiomed have?

The company employs 2,003 workers across the globe.

Does Abiomed have any subsidiaries?
The following companies are subsidiares of Abiomed: ABD Holding Company, ABIOMED Athlone Ltd, ABIOMED Australia Pte. Ltd, ABIOMED Europe, ABIOMED Japan KK, ABIOMED Limited, ABIOMED R&D, ABIOMED SARL, ABIOMED Singapore Pte. Ltd, AIS GmbH Aachen Innovative Solutions, ECP Entwicklungsgesellschaft mbH, and Impella Cardiosystems.
Read More
How can I contact Abiomed?

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The official website for the company is www.abiomed.com. The medical equipment provider can be reached via phone at (978) 646-1400, via email at ir@abiomed.com, or via fax at 978-777-8411.

This page (NASDAQ:ABMD) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -